+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Multiple Myeloma Drug Market by Drug Class, Line of Therapy, Treatment Regimen, Route of Administration, Distribution Channel, Patient Age, Gender - Global Forecast to 2030- Product Image
Multiple Myeloma Drug Market by Drug Class, Line of Therapy, Treatment Regimen, Route of Administration, Distribution Channel, Patient Age, Gender - Global Forecast to 2030- Product Image
Sale

Multiple Myeloma Drug Market by Drug Class, Line of Therapy, Treatment Regimen, Route of Administration, Distribution Channel, Patient Age, Gender - Global Forecast to 2030

  • PDF Icon

    Report

  • 189 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4968786
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Multiple Myeloma Drug Market grew from USD 24.51 billion in 2024 to USD 26.52 billion in 2025. It is expected to continue growing at a CAGR of 8.07%, reaching USD 39.05 billion by 2030.

Introduction to the Multiple Myeloma Treatment Landscape

Multiple myeloma remains one of the most challenging hematologic malignancies, imposing a significant clinical and economic burden worldwide. Recent years have witnessed remarkable advances in therapeutic modalities, driven by deeper understanding of disease biology and a relentless pursuit of innovative treatments. As novel agents move from bench to bedside, stakeholders face the dual imperative of optimizing patient outcomes while navigating complex regulatory, reimbursement, and competitive landscapes.

This executive summary distills the critical forces shaping the multiple myeloma drug market. It frames the current state of play, highlights disruptive trends, and underscores the strategic considerations that industry leaders must address to thrive. By synthesizing insights across therapy classes, lines of therapy, routes of administration, patient demographics, and regional dynamics, this analysis offers a holistic view of emerging opportunities and potential obstacles. The aim is to equip both seasoned experts and newly engaged decision-makers with the knowledge needed to make informed choices in drug development, market access, and commercialization.

Emerging Trends Redefining Treatment Paradigms

The multiple myeloma treatment paradigm is undergoing a profound transformation as precision medicine and immunotherapy converge to redefine standards of care. Monoclonal antibodies, once a nascent class, have become central to frontline and relapsed settings, offering targeted mechanisms that augment cytotoxic regimens. Simultaneously, proteasome inhibitors continue to evolve with newer oral formulations that enhance patient convenience and adherence.

Beyond pharmacologic innovations, the emphasis on combination regimens has intensified, with quadruplet therapies emerging as a viable approach for high-risk patients. Digital health platforms and real-world evidence initiatives are also shaping treatment pathways, enabling clinicians to tailor regimens according to individual risk profiles and tolerability. This shift towards data-driven personalization, coupled with an expanding arsenal of immunomodulatory agents, underscores a broader industry push to balance efficacy with quality of life. In turn, these transformative trends are redefining competitive dynamics and accelerating the pace of clinical development.

Assessing the Impact of US Tariff Changes in 2025

In 2025, the introduction of updated tariff structures in the United States is poised to alter cost parameters across the multiple myeloma drug supply chain. Heightened import duties on active pharmaceutical ingredients may drive up manufacturing expenses, prompting producers to reassess sourcing strategies. These changes coincide with ongoing pressures on reimbursement rates, creating a delicate balance between maintaining affordable patient access and preserving healthy profit margins.

Manufacturers are already exploring mitigation tactics such as near-term pricing adjustments, strategic stockpiling, and greater vertical integration of raw material production. Payers are likely to respond by intensifying formulary negotiations, demanding more robust pharmacoeconomic data to justify premium pricing. Ultimately, these tariff-induced cost shifts will catalyze closer collaboration among suppliers, payers, and providers to ensure continuity of care and sustainable market economics.

Insights Across Drug Classes and Patient Profiles

Examining the market through the lens of drug class reveals that proteasome inhibitors maintain a leading role, buoyed by established agents and next-generation oral formulations that resonate with patient preference for at-home administration. Immunomodulatory agents, led by lenalidomide, continue to dominate chronic management protocols, while newer entrants such as pomalidomide and thalidomide diversify therapeutic choices. Monoclonal antibodies, driven by daratumumab’s rapid adoption, are expanding into earlier lines of therapy. Histone deacetylase inhibitors remain a more niche category, with panobinostat reserved for specific refractory cases.

Assessing lines of therapy highlights a shift toward aggressive first-line regimens, where combining multiple mechanisms of action seeks to delay relapse and extend overall survival. In the second and third lines and beyond, the preference for combination therapies persists, with triplet and quadruplet regimens emerging as standards for fit patients. The route of administration dimension underscores growing interest in subcutaneous delivery for improved patient experience, while oral therapies continue to gain traction in outpatient settings.

Distribution channels also contribute to market evolution, with hospital pharmacies retaining prominence for infusion-based treatments and online pharmacies capturing a growing share of oral oncology prescriptions. Patient age and gender further refine market potential: patients aged sixty and above represent the bulk of incidence, though under-sixty populations require tailored dose and toxicity management. Gender dynamics show a slightly higher prevalence in males, guiding targeted education and support programs.

Regional Variations Influencing Market Dynamics

Across the Americas, robust healthcare infrastructure and established reimbursement frameworks have propelled rapid uptake of novel multiple myeloma therapies. North America leads global clinical development and benefits from streamlined regulatory pathways, while Latin America presents pockets of growth driven by public-private partnerships aimed at expanding drug access.

In Europe, Middle East & Africa, heterogeneous regulatory regimes and variable payer willingness create a patchwork of market opportunity. Western European markets absorb innovations more swiftly, supported by adaptive licensing agreements, whereas emerging economies in North Africa and parts of the Middle East rely on tiered pricing and international aid programs.

Asia-Pacific is marked by accelerating disease incidence and expanding healthcare budgets. Japan and Australia continue to mirror Western treatment patterns, while China and India prioritize localization of manufacturing and reimbursement negotiation. The evolving landscape in this region reflects a balance between cost containment and the drive to adopt cutting-edge therapies as disposable incomes and insurance coverage broaden.

Competitive Snapshot of Leading Market Participants

The competitive arena is dominated by a handful of multinational biopharmaceutical firms whose portfolios span established blockbusters and late-stage pipelines. Major players have pursued strategic acquisitions to bolster their immunotherapy and proteasome inhibitor franchises, while emerging biotech companies focus on innovative mechanisms such as bispecific antibodies and CAR-T cell therapies.

Partnerships between large and mid-sized companies have accelerated clinical trial enrollment and diversified geographic reach. Collaborations with contract research organizations and manufacturing partners are optimizing development timelines and cost efficiencies. Amid these alliances, new entrants are carving niches by targeting unmet needs in refractory patient populations and exploring biomarker-driven approaches.

Competitive differentiation increasingly hinges on real-world data generation, patient support programs, and strategic engagement with key opinion leaders. Firms that effectively integrate these elements into their commercialization plans are best positioned to capture market share and navigate evolving access challenges.

Strategies for Advancing Market Leadership

Industry leaders should prioritize integrated development of combination regimens that leverage complementary mechanisms of action and enhance depth of response. Investing in subcutaneous and oral formulations will meet growing patient demands for convenient administration and reduce clinical burden on infusion centers.

Securing supply chain resilience through geographic diversification of active ingredient suppliers will mitigate tariff-related cost fluctuations. Early engagement with payers to align on value frameworks and incorporate health economics outcomes research will streamline reimbursement negotiations. Establishing collaborative networks with patient advocacy groups and community oncology centers will deepen market penetration and support adherence initiatives.

Leveraging digital health analytics to capture real-world evidence and monitor long-term outcomes can inform iterative improvements in treatment protocols. By combining these strategic imperatives, companies can strengthen their competitive position and drive sustainable growth in the multiple myeloma market.

Comprehensive Approach to Market Research Methodology

This analysis integrates both secondary and primary research to deliver a comprehensive market perspective. Initially, peer-reviewed journals, clinical trial registries, regulatory filings, and company disclosures were reviewed to map the current therapeutic landscape and identify active pipelines. Proprietary databases provided historical sales and prescription data, enabling validation of emerging trends.

Primary research was conducted through in-depth interviews with oncologists, payers, pharmacy directors, and patient advocacy representatives across key regions. These insights ensured that projected shifts aligned with clinical practice patterns and payer priorities. Data triangulation techniques were applied to reconcile discrepancies between secondary sources and expert feedback.

Market segment definitions were rigorously tested against emerging therapy categories and patient demographics. Regional market models were calibrated using country-specific epidemiology, healthcare expenditure metrics, and regulatory timelines. Quality checks at each stage guaranteed methodological transparency and reproducibility of findings.

Synthesis of Key Findings and Strategic Implications

This executive summary has outlined the dynamic interplay of scientific innovation, regulatory evolution, and economic pressures shaping the multiple myeloma drug market. Segmentation by drug class and patient profile underscores the significance of personalized treatment strategies, while regional analyses reveal diverse routes to market access and adoption.

The anticipated impact of tariff adjustments in the United States signals the need for agile supply chain management and proactive payer engagement. Competitive intelligence highlights the importance of strategic alliances and real-world evidence in differentiating product offerings. Collectively, these insights equip stakeholders with a roadmap to navigate complexities and harness growth opportunities.

As the therapeutic frontier in multiple myeloma expands, sustained success will depend on aligning clinical innovation with operational excellence and value-focused collaborations. Decision-makers who integrate these elements will be best positioned to improve patient outcomes and secure a leading market position.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Class
    • Histone Deacetylase Inhibitors
      • Panobinostat
    • Immunomodulatory Agents
      • Lenalidomide
      • Pomalidomide
      • Thalidomide
    • Monoclonal Antibodies
      • Daratumumab
      • Elotuzumab
      • Isatuximab
    • Proteasome Inhibitors
      • Bortezomib
      • Carfilzomib
      • Ixazomib
  • Line Of Therapy
    • First Line
    • Second Line
    • Third And Beyond
  • Treatment Regimen
    • Combination Therapy
      • Doublet Regimen
      • Quadruplet Regimen
      • Triplet Regimen
    • Monotherapy
  • Route Of Administration
    • Intravenous
    • Oral
    • Subcutaneous
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Patient Age
    • Sixty And Above
    • Under Sixty
  • Gender
    • Female
    • Male
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Bristol-Myers Squibb Company
  • Janssen Biotech, Inc.
  • Takeda Pharmaceutical Company Limited
  • Amgen Inc.
  • Novartis International AG

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Multiple Myeloma Drug Market, by Drug Class
8.1. Introduction
8.2. Histone Deacetylase Inhibitors
8.2.1. Panobinostat
8.3. Immunomodulatory Agents
8.3.1. Lenalidomide
8.3.2. Pomalidomide
8.3.3. Thalidomide
8.4. Monoclonal Antibodies
8.4.1. Daratumumab
8.4.2. Elotuzumab
8.4.3. Isatuximab
8.5. Proteasome Inhibitors
8.5.1. Bortezomib
8.5.2. Carfilzomib
8.5.3. Ixazomib
9. Multiple Myeloma Drug Market, by Line of Therapy
9.1. Introduction
9.2. First Line
9.3. Second Line
9.4. Third and Beyond
10. Multiple Myeloma Drug Market, by Treatment Regimen
10.1. Introduction
10.2. Combination Therapy
10.2.1. Doublet Regimen
10.2.2. Quadruplet Regimen
10.2.3. Triplet Regimen
10.3. Monotherapy
11. Multiple Myeloma Drug Market, by Route of Administration
11.1. Introduction
11.2. Intravenous
11.3. Oral
11.4. Subcutaneous
12. Multiple Myeloma Drug Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Multiple Myeloma Drug Market, by Patient Age
13.1. Introduction
13.2. Sixty and Above
13.3. Under Sixty
14. Multiple Myeloma Drug Market, by Gender
14.1. Introduction
14.2. Female
14.3. Male
15. Americas Multiple Myeloma Drug Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Multiple Myeloma Drug Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Multiple Myeloma Drug Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Bristol-Myers Squibb Company
18.3.2. Janssen Biotech, Inc.
18.3.3. Takeda Pharmaceutical Company Limited
18.3.4. Amgen Inc.
18.3.5. Novartis International AG
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. MULTIPLE MYELOMA DRUG MARKET MULTI-CURRENCY
FIGURE 2. MULTIPLE MYELOMA DRUG MARKET MULTI-LANGUAGE
FIGURE 3. MULTIPLE MYELOMA DRUG MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2024 VS 2030 (%)
FIGURE 20. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. MULTIPLE MYELOMA DRUG MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. MULTIPLE MYELOMA DRUG MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. MULTIPLE MYELOMA DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PANOBINOSTAT, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LENALIDOMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY POMALIDOMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THALIDOMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DARATUMUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ELOTUZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ISATUXIMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY BORTEZOMIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY CARFILZOMIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IXAZOMIB, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THIRD AND BEYOND, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DOUBLET REGIMEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY QUADRUPLET REGIMEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TRIPLET REGIMEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SIXTY AND ABOVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY UNDER SIXTY, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FEMALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 76. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 77. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 78. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 79. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 80. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 81. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 82. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 83. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 84. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 87. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 88. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 89. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 90. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 91. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 92. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 93. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 94. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 95. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 96. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 98. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 99. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 137. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 138. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 149. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 150. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 151. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 152. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 153. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 154. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 155. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 156. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 157. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 158. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 159. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 160. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 161. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 162. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 163. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 164. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 165. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 166. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 167. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 168. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 169. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 171. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 172. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 173. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 174. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 175. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 176. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 177. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 178. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 179. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 180. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 181. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 182. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 183. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 184. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 185. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 186. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 187. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 188. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 189. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 190. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 191. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 192. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 193. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 195. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 196. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 197. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 198. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 199. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 200. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 201. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 202. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 203. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 204. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 205. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 206. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 208. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 209. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 210. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 211. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 212. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 213. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 214. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 215. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 217. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 218. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 221. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 222. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 223. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 224. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 225. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 226. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 228. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 232. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 233. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 234. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 235. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 236. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 238. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 245. DENMARK MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 246. DENMARK MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 247. DENMARK MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 248. DENMARK MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 249. DENMARK MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 250. DENMARK MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 251. DENMARK MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 252. DENMARK MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 253. DENMARK MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. DENMARK MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 255. DENMARK MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 256. DENMARK MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 257. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 258. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 259. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 260. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 261. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 262. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 263. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 264. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 265. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 266. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 267. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 268. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 269. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 270. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 271. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 272. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 273. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 274. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 275. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 276. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 277. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 278. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 279. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 280. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 281. FINLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 282. FINLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 283. FINLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 284. FINLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 285. FINLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 286. FINLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 287. FINLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 288. FINLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 289. FINLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 290. FINLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 291. FINLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 292. FINLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 293. SWEDEN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 294. SWEDEN MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 295. SWEDEN MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 296. SWEDEN MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 297. SWEDEN MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 298. SWEDEN MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 299. SWEDEN MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 300. SWEDEN MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 301. SWEDEN MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 302. SWEDEN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 303. SWEDEN MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 304. SWEDEN MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 305. NIGERIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 306. NIGERIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 307. NIGERIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE 308. NIGERIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 309. NIGERIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2030 (USD MILLION)
TABLE 310. NIGERIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 311. NIGERIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2030 (USD MILLION)
TABLE 312. NIGERIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 313. NIGERIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 314. NIGERIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 315. NIGERIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 316. NIGERIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 317. EGYPT MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 318. EGYPT MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 319. EGYPT MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2030 (USD MILLION)
TABLE

Companies Mentioned

The companies profiled in this Multiple Myeloma Drug market report include:
  • Bristol-Myers Squibb Company
  • Janssen Biotech, Inc.
  • Takeda Pharmaceutical Company Limited
  • Amgen Inc.
  • Novartis International AG

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages189
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 26.52 Billion
Forecasted Market Value ( USD ) by 2030 $ 39.05 Billion
Compound Annual Growth Rate8.0%
Regions CoveredGlobal
No. of Companies Mentioned6

Related Topics

Related Reports

Multiple Myeloma Therapeutics Market by Drug Class, Treatment Line, Mode of Administration, Distribution Channel, Product Type - Global Forecast to 2030 - Product Image

Multiple Myeloma Therapeutics Market by Drug Class, Treatment Line, Mode of Administration, Distribution Channel, Product Type - Global Forecast to 2030

  • Report
  • 197 Pages
  • Global
From
Multiple Myeloma Therapeutics Market Size, Share & Trends Analysis Report By Drug, By Disease (Active Multiple Myeloma, Smoldering Multiple Myeloma), By End Use, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Multiple Myeloma Therapeutics Market Size, Share & Trends Analysis Report By Drug, By Disease (Active Multiple Myeloma, Smoldering Multiple Myeloma), By End Use, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 80 Pages
  • Global
From
Multiple Myeloma - Market Insight, Epidemiology, and Market Forecast - 2034 - Product Image

Multiple Myeloma - Market Insight, Epidemiology, and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Multiple Myeloma Drugs Market Report by Therapy, Drug Type, End-User, Distribution Channel, and Region 2024-2032 - Product Image

Multiple Myeloma Drugs Market Report by Therapy, Drug Type, End-User, Distribution Channel, and Region 2024-2032

  • Report
  • 138 Pages
  • Global
From
Multiple Myeloma Drugs Market Report 2025 - Product Image

Multiple Myeloma Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From

About the Multiple Myeloma Drug Market

Multiple Myeloma is a type of cancer that affects the plasma cells in the bone marrow. It is a form of Leukemia, and is the second most common type of blood cancer. Treatment for Multiple Myeloma typically involves a combination of chemotherapy, radiation therapy, and targeted drug therapy. The Multiple Myeloma drug market is composed of a variety of drugs, including proteasome inhibitors, immunomodulatory agents, monoclonal antibodies, and other targeted therapies. These drugs are used to treat the disease, as well as to reduce the risk of relapse. The Multiple Myeloma drug market is highly competitive, with many companies offering a range of treatments. Some of the major players in the market include Bristol-Myers Squibb, Celgene, Novartis, Amgen, and Johnson & Johnson. Other companies such as Merck, Pfizer, and Takeda are also active in the market. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.